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Abstract
Cancer has long been considered a disease that mimics an “unhealed wound,” with oncogene-induced secretory
activation signals from epithelial cancer cells facilitating stromal fibroblast, endothelial, and inflammatory cell par-
ticipation in tumor progression. However, the underlying mechanisms that orchestrate cooperative interaction
between malignant epithelium and the stroma remain largely unknown. Here, we identified interleukin-1β (IL-1β) as
a stromal-acting chemokine secreted by ovarian cancer cells, which suppresses p53 protein expression in cancer-
associated fibroblasts (CAFs). Elevated expression of IL-1β and cognate receptor IL-1R1 in ovarian cancer epithelial
cells and CAFs independently predicted reduced overall patient survival, as did repressed nuclear p53 in ovarian
CAFs. Knockdown of p53 expression in ovarian fibroblasts significantly enhanced the expression and secretion of
chemokines IL-8, growth regulated oncogene-alpha (GRO-α), IL-6, IL-1β, and vascular endothelial growth factor
(VEGF), significantly increased in vivo mouse xenograft ovarian cancer tumor growth, and was entirely dependent
on interaction with, and transcriptional up-regulation of, nuclear factor-kappaB (NF-κB) p65. Our results have uncov-
ered a previously unrecognized circuit whereby epithelial cancer cells use IL-1β as a communication factor instructing
stromal fibroblasts through p53 to generate a protumorigenic inflammatory microenvironment. Attenuation of p53
protein expression in stromal fibroblasts generates critical protumorigenic functionality, reminiscent of the role that
oncogenic p53 mutations play in cancer cells. These findings implicate CAFs as an important target for blocking
inflammation in the tumor microenvironment and reducing tumor growth.
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Introduction
Cancers interact with a richly diverse stromal microenvironment
composed of mesenchymal, endothelial, immunoregulatory, and
hematopoietic cells to foster tumor growth and progression [1]. Many
microenvironment components involved in cancer development are
also involved in the wound healing process. Cancer has been long rec-
ognized as an “unhealed wound” [2], and the key component of wound
healing is inflammatory signal network modulation. Although well
regulated in normal wound healing, the role of inflammatory mediators
in regulating cancer is largely undefined. As the predominant cellular
component of the tumor microenvironment [3], fibroblasts play a criti-
cal synergistic role by working with oncogenic cells to facilitate initia-
tion and progression toward clinically recognizable tumor [4,5].
Indeed, paracrine secretory activation of tumor stroma yields a micro-
environment replete with inflammatorymediators, growth factors, extra-
cellular matrix (ECM) modifiers, and angiogenic factors [6–8],
selectively stimulating aggressive tumorigenesis. Cancer epithelium–
secreted stimulatory factors induce transition of normal fibroblasts to
a reactive, synthetic, tumor-promoting cancer-associated fibroblast
(CAF) phenotype. Yet, a detailed mechanism linking coordinate regu-
lation of these disparate components to promote growth of ovarian
cancer is not well understood.
Ovarian cancer is the deadliest gynecologic malignancy in women
in the United States [9]. Dismal prognosis is due, in part, to incom-
plete understanding of the mechanisms controlling development.
Integrated genomic analysis has identified mutation of the TP53 tumor
suppressor gene, encoding the p53 transcription factor, in 96% of
high-grade serous ovarian cancer patients [10]. In addition to the well-
known effect of p53 in maintaining genomic integrity despite DNA
damage or instability through apoptosis regulation [11], p53 is known
to function in regulation of inflammation [12]. Whereas most studies
have focused on p53 function in epithelial cancer cells, limited knowl-
edge is available for the role of p53 in the most abundant component of
cancer stroma, fibroblasts. While p53 expression in CAFs has been rec-
ognized [13,14], its regulation and functional role in tumor pathogenesis
is not known.
Inflammation is a long-recognized risk factor for ovarian cancer [15]
and a hallmark of almost all cancers [16]. The inflammatory response
is involved in almost all stages of tumor development [17]. Inflamma-
tion of the peritoneum, classically associated with ovarian cancer, has
been tied to elevated ovarian stromal expression of multiple cytokines
and chemokines, all of which are downstream targets of the transcrip-
tional factor NF-κB [18,19]. NF-κB is constitutively activated in many
tumor cells [20]. NF-κB activation provides a critical link between in-
flammation and cancer development [21], whereas NF-κB inhibition
suppresses tumor growth, leading to the concept of “NF-κB addiction”
in cancer cells [22]. We previously demonstrated that overexpression of
oncogenic alleles of HRAS and KRAS in immortalized human ovarian
surface epithelial cells activated secretion of a group of multiple cyto-
kines and chemokines in an NF-κB–dependent manner [23], iden-
tifying one group member, GRO-α, as capable of inducing ovarian
stromal fibroblast senescent activation, promoting ovarian tumorigen-
esis [24]. However, although senescent fibroblasts composed only a
small percentage of the tumor microenvironment, the signaling mech-
anism by which ovarian cancer cells communicated successfully with
nonsenescent fibroblasts (the largest component of the tumor micro-
environment) remained unknown. Therefore, we hypothesized that
additional chemokines secreted by ovarian cancer cells may function
as critical communication signals promoting synergistic alteration and
reprogramming of adjacent stromal fibroblasts to synchronize with
cancer epithelial cells in promoting cancer growth. We present data
demonstrating that interleukin-1β (IL-1β) is a critical chemokine in-
volved in the communication between cancer cells and stromal
fibroblasts, acting to facilitate the development of ovarian cancer
through the generation of a protumorigenic inflammatory phenotype
in stromal fibroblasts.
Materials and Methods
Patients, Clinicopathologic Data, and Ovarian Cancer
Tissue Microarrays
Five hundred twenty-seven representative tumor samples and rele-
vant clinical data were obtained from women diagnosed with primary
ovarian carcinoma that underwent initial surgery at The University of
Texas MD Anderson Cancer Center (UTMDACC) between January
1990 and April 2010. Relevant clinical data were collected by retro-
spective review of the patient pathology reports and used in gener-
ating an identity-free patient clinical factor follow-up database. The
Institutional Review Board at the UTMDACC approved the use of
both archival tissue blocks and chart reviews. The median age of the
527 patients in our study was 60 years (range, 20–92 years). The mean
overall survival time was 7.8 years (95% CI, 3.5–4.6 years), and the
overall survival rates were 59% (95% CI, 0.55–0.63) at 3 years, 39%
(95% CI, 0.34–0.44) at 5 years, and 27% (0.22–0.32) at 10 years.
Histopathology diagnoses were based on World Health Organization
criteria, tumor grading for nonserous carcinomas was based on the
Gynecologic Oncology Group criteria, and disease staging was assigned
according to the International Federation of Gynecology and Obstetrics
staging system. Serous carcinomas were graded by using a two-tier
system (low grade and high grade) according to established criteria.
Archived tissue microarray paraffin blocks were constructed from rep-
resentative patient core samples using morphologically representative
areas of blocks, as we have previously described [25].
Immunohistochemical Staining and Statistical Analysis
Ovarian cancer tissue microarray slides were subjected to immuno-
histochemical (IHC) staining according to the manufacturer’s pro-
tocol (Biocare Medical, Concord, CA) and following our previously
published protocols [25,26]. Briefly, after initial deparaffinization/
hydration, epitopes were unmasked using the Universal Decloaker
(UD1000) and the Decloaking Chamber pressure cooker (DC2002),
endogenous peroxidases were blocked by Peroxidazed 1 (PX968), and
nonspecific binding was blocked by Background Sniper (BS966) and
Avidin-Biotin blocking reagents (AB972). Slides were then incubated
overnight at 4°C with primary antibodies: p53 (1:75; Santa Cruz Bio-
technology, Dallas, TX,DO-1 sc-126), phospho-Y496–IL-1R1 (1:500;
Abcam, Cambridge, MA, ab59995), or IL-1β (1:1000; Santa Cruz
Biotechnology, sc-7884). Primary antibodies were followed by incuba-
tion with biotin-labeled Universal Goat Link secondary reagent (GU600)
for 15 minutes, Streptavidin-HRP (HP604) for 15 minutes, staining for
5 minutes with 3,3-diaminobenzidine (DB801), counterstaining with
hematoxylin, dehydration, and mounting in Permount. Negative con-
trols included replacing the primary antibody with phosphate-buffered
saline (PBS). IHC staining was analyzed by two gynecological pathol-
ogists (by J.L. and J.Z.). Staining was scored according to tumor stroma
nuclear p53, cytoplasmic IL-1β, and IL-1R1 immunoreactivity in ovar-
ian cancer epithelial cells and cancer-proximal stromal fibroblasts using
the software and hardware of the Applied Imaging Ariol automated
410 Interleukin-1β Promotes Ovarian Tumorigenesis Schauer et al. Neoplasia Vol. 15, No. 4, 2013
image analysis system (Molecular Devices, Inc, Sunnyvale, CA, SL-50).
The degree of staining in tumor microarray cores was quantified using a
grading system based on positive percentage: score = 0 for <10%positive
fibroblasts, score = 1 for 10% to 20% positive fibroblasts, score = 2 for
20% to 50% positive fibroblasts, score = 3 for 50% to 70% positive
fibroblasts, and score = 4 for 70% to 100% positive fibroblasts. For
all statistical analyses, scoring was grouped according to low expression
and high expression, as indicated in the figures and figure legends.
Fisher’s exact test was used to evaluate the association of p53, cyto-
plasmic IL-1β, and IL-1R1 with clinical factors. The Kaplan-Meier
method was used to estimate the probability of overall survival, and
the Mantel-Cox log-rank test was used to compare the overall survival
or disease-free survival between different comparison groups. Multi-
variate Cox regression models were fitted to determine whether p53,
cytoplasmic IL-1β, and IL-1R1 correlation with overall patient survival
achieved independent predictor status after adjusting/challenging by
the clinical factors of International Federation of Gynecology and
Obstetrics (FIGO) stage (I–IV), clinical response (as defined above),
and grade (1–3). Results were considered statistically significant at
the P ≤ .05 level. SPSS PASW17.0.2 software (IBM, Inc, Armonk,
NY) was used for all statistical analyses.
Ovarian Tissue–Derived and Established Ovarian Line
Cell Culture
For the purpose of continuous in vitro culturing, we previously
established human telomerase reverse transcriptase overexpressing
normal ovarian fibroblast cell lines [24]. Multiple lines of these ex-
tended replication fibroblasts were used for this study, which achieve
consistently higher passage number and display elevated prolifera-
tion capacity relative to unaltered primary parent fibroblast lines
(Figure W1). CAF cell cultures were collected and isolated according
to our protocol approved by the UTMDACC Institutional Review
Board and were grown and maintained as we have previously pub-
lished [24]. T29 cells were derived from the normal, immortalized
nontumorigenic ovarian surface epithelial cell line IOSE-29 express-
ing human telomerase catalytic subunit and SV40 T/t antigens by
transfection and confirmed as nontumorigenic as previously described
[23]. SKOV3 malignant ovarian cancer cells were maintained and used
as we have previously published [23].
Establishment of Stably Expressing hTERT, p53i, and p65i
Ovarian Fibroblasts
Retroviruses carrying hTERT cDNA or p53 siRNA, or lenti-
viruses carrying p65 shRNA plasmid, were generated and harvested
as described previously [23]. All fibroblast lines were generated by
two rounds of infection by generated retrovirus or lentivirus, fol-
lowed by stable selection with hygromycin (100 μg/ml), neomycin
(400 μg/ml), or puromycin (1.0 μg/ml) for 10 to 14 days. Retrovirus
infection efficiency was determined by follow-up with Western blot
for the factor being repressed (as shown in figures), and lentiviral
infection efficiency was determined by green fluorescence observed
using the integrated internal ribosome entry site fused to the enhanced
variant of green fluorescent protein (IRES-EGFP) element in the
pGIPZ vector.
Western Blot Analysis
Western blot analysis was performed as we have previously described
[27]. Briefly, cell lysates were prepared using a radioimmunoassay-
based lysis buffer: 50 mM Tris-HCl (pH 8), 150 mM NaCl, 1%
NP-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl
sulfate with a protease inhibitor cocktail added before use (Roche,
Indianapolis, IN). Protein concentrations were measured using the
Bio-Rad (Hercules, CA) protein assay kit, followed by overnight
primary antibody incubation at 4°C at the following dilutions: β-actin
at 1:30,000 (Sigma, St Louis, MO, A5691), CXCR2 at 1:500 (R&D
Systems, Minneapolis, MN, MAB331), GRO-α at 1:500 (Sigma,
G7659), hTERT at 1:1000 (GeneTex, Irvine, CA, GTX30410), IL-1α
at 1:500 (R&D Systems, MAB200), IL-1β at 1:500 (Santa Cruz Bio-
technology, sc-7884), IL-1R1 at 1:1000 (Santa Cruz Biotechnology,
sc-25775), IL-6 at 1:500 (Santa Cruz Biotechnology, sc-7920), IL-8 at
1:200 (R&D Systems, AF-208-NA), p53 at 1:500 (Santa Cruz Bio-
technology, DO-1 sc-126), p65 at 1:500 (Abcam, ab7970), phospho-
S276-p65 at 1:000 (Cell Signaling Technology, Danvers, MA, #3037),
SDF-1α at 1:1000 (Abcam, ab80118), super-activator of chemokine
signaling 1 (SOCS1) at 1:500 (Abcam, ab62584), TFIIB at 1:1000
(Santa Cruz Biotechnology, sc-274), tumor necrosis factor (TNF)
receptor–associated factor 6 (TRAF-6) at 1:1000 (Abcam, ab13853),
γ-tubulin at 1:1000 (Sigma, T5192), and vascular endothelial growth
factor (VEGF) at 1:1000 (Santa Cruz Biotechnology, sc-152), and
then secondary antibody incubation using sheep anti-mouse HRP
(GE Healthcare, Pittsburgh, PA, RPN4201), goat anti-rabbit HRP
(GE Healthcare, RPN4301), or donkey anti-goat (Santa Cruz Bio-
technology, sc-2020) at 1:3000. Films were developed from blots
incubated using the ECLplus kit (Amersham Biosciences, Piscataway,
NJ) and exposure times of 30 seconds to 15 minutes.
Analysis of Cell Proliferation
To analyze cell proliferation, 2750 cells or 3500 cells were seeded
onto 96-well plates in N = 8 wells, including three control wells with
cell growth media only. Cells were incubated at 37°C and 5% CO2.
Proliferation was assessed 24, 48, 60, and 72 hours later in triplicate
based on the colorimetric MTT cell proliferation assay (ATCC,
Manassas, VA, 30-1010K) according to the manufacturer’s protocol.
Assays were repeated in triplicate and are reported in the Supplemen-
tary Materials.
Evaluation of Cell Cycle Progression and Apoptotic Status
The cell cycle progression status cell lines was evaluated following
trypsinization, two washes in PBS, and resuspension at 1 × 106 to 2 ×
106 in 200 μl of PBS. Cells were fixed in cold 75% ethanol for a
minimum of 4 hours at 4°C, washed twice with PBS, resuspended in
200 μl of PBS, and incubated with 20 μl of RNase (1 mg/ml, Sigma) at
37°C for 15 to 20 minutes before staining with 200 μl of propidium
iodide (PI; 50 μg/ml, Sigma). For apoptosis analysis, cells were
harvested by trypsinization at 75% confluence, washed twice with
PBS, and stained with fluorescein isothiocyanate–Annexin V and PI
(BD Pharmingen, Franklin Lakes, NJ, 556547). Experiments were
performed in duplicate and repeated twice. Determination of both
cell cycle progression and apoptotic index was performed using a
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) run-
ning BD CellQuest Pro version 5.1 software in the Flow Cytometry
and Cellular Imaging Facility at UTMDACC. The percentage of
apoptotic cells was calculated on the basis of the height of the M1
peak along the Annexin V and PI biparametric cytogram, representing
the combined early and late apoptotic cell populations among the total
cell population analyzed.
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Co-immunoprecipitation
Binding complex association between p53 and p65 was evaluated
using a co-immunoprecipitation (co-IP) kit (Thermo Scientific,Waltham,
MA, Cat. No. 26149), following the manufacturer’s suggested proto-
col. Briefly, 10 μg of p53 (Santa Cruz Biotechnology, sc-126) or p65
(Abcam, ab7970) antibody was conjugated to the AminoLink Plus
coupling resin beads and washed extensively. Normal ovarian fibroblast
cell lysates were harvested from 80% confluent 60-mm dishes (seeded
equivalently) using the IP/lysis buffer by alternating incubation on ice
and extensive scrapping (two each), then pre-cleared using the control
agarose resin beads for 2 hours at room temperature, and incubated
overnight at 4°C on separate p53- and p65-conjugated bead resin col-
umns. After extensive washing, bound proteins were eluted using elution
buffer in 50-μl total volume for immediate analysis of total elution by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis on 10% gels,
subsequent Western blot analysis.
Dual-Luciferase Reporter Assay
NF-κB promoter activation status was determined using the
Dual-Luciferase Reporter Assay System (Promega, Sunnyvale, CA,
TM040) following the manufacturer’s suggested protocol. Briefly,
the above-listed normal ovarian fibroblast cell lines were transiently
co-transfected using the FuGene6 commercial protocol with plasmids
containing either two wild-type or two mutant truncated engineered
NF-κB response minimal promoter elements upstream of the firefly
luciferase 3 gene [23], in combination with the pRL-CMV vector (Pro-
mega, E2261) that expresses Renilla luciferase driven by the CMV
intermediate promoter. Normal ovarian fibroblast cell lysates were
harvested 36 hours after co-transfection in 400 μl of cold passive lysis
buffer using a plastic scrapper from 60-mm dishes at 80% confluence
(seeded equivalently), immediately subjected to two cycles of freeze/
thaw, and then centrifuged at 4°C at maximum speed for 15 minutes
to pellet cell debris. Twenty microliters of cleared cell lysates was used
for each assay reading on a DLR Luminometer (Turner BioSystems,
Sunnyvale, CA, P/N 9600-001), setup for a 20-second wavelength pulse
read for each luciferase. Data are reported as the ratio of detection for
firefly/Renilla luciferases in relative light units standardized according to
total protein concentration for each lysate. Experiments were repeated
twice with N = 4 samples.
Xenograft in Athymic Nude Mouse and Statistical Analysis
To determine the effect on fibroblast tumor contribution in the
absence of p53 or p65 on xenograft tumor formation and growth
in vivo, normal ovarian fibroblast 151 cells expressing hTERT, hTERT
plus p65 inhibition, hTERT plus p53 inhibition, or hTERT plus
double-inhibition constructs targeting p53 and p65 were counted
using trypan blue to indicate viable cells and then were combined in
a 1:4 ratio (fibroblasts/epithelial cells) with viable-counted T29 or
SKOV3 ovarian epithelial cells. T29 cells (4 × 106) were combined with
1 × 106 fibroblasts, and 1 × 106 SKOV3 cells were combined with 2.5 ×
105 fibroblasts for each injection type. Cell combinations were imme-
diately washed twice with PBS, resuspended in 150 μl of PBS, and in-
jected subcutaneously into 4- to 6-week-old Swiss nu-nu/Ncr athymic
nude mouse hind flank (outbred mouse colony maintained by the
Department of Experimental Radiation Oncology at UTMDACC).
The mice were housed and cared for in the UTMDACC pathogen-free
experimental animal facility and checked every 2 days for tumors. The
date on which the first grossly visible tumors appeared was recorded,
and tumor size was monitored thereafter every 2 to 3 days. Mice were
sacrificed after 13 weeks of follow-up, or according to the occurrence of
excessive tumor burden. Tumors were removed, fixed in 10% formalin,
and subjected to routine histologic examination. All mouse experi-
ments followed our Institutional Animal Care and Use Committee
(IACUC)-approved animal protocol.
Statistically significant differences in the rate of tumor growth
between xenografts produced with cancer cells combined with fibro-
blasts attenuated for p53 or p65 (or both) and their parental control
cell injections were calculated using linear, nonparametric regression
analysis. Statistically significant differences in tumor growth curves
between xenograft implants of ovarian epithelial cells with fibroblasts
with attenuated p53 or p65 (or both) and their parental control
cells were calculated using the Student’s t test or analysis of variance
(ANOVA), as indicated. All results were considered statistically sig-
nificant at the P < .05 confidence level, using SPSS17.02 software
(IBM, Inc).
Results
Ovarian Cancer Cell–Derived IL-1β Paracrinely Represses
p53 Protein Expression in Ovarian Fibroblasts
We hypothesized that p53 is the key sensor in stromal fibroblasts
involved in the regulation of communication between cancer epithelial
cells and fibroblasts. Thus, we first analyzed p53 protein levels in
human telomerase reverse transcriptase (hT) immortalized ovarian
fibroblasts (Figure W1) following treatment with media conditioned
by ovarian cancer cells. As shown in Figure 1A, attenuation of p53
levels in ovarian fibroblasts occurred after only 8 hours of exposure
to media conditioned by the SKOV3 ovarian cancer cell line, while
p53 attenuation occurred 12, 16, and especially 24 hours after expo-
sure to HRAS-transformed ovarian epithelial cell (T29H)–conditioned
media (Figure 1B). To identify specific paracrine factors involved in
repression of p53, we examined multiple cytokines commonly secreted
by cancer epithelial cells and RAS-transformed tumorigenic cells in-
cluding IL-1β, IL-8, IL-6, and GRO-α [23]. Ovarian fibroblasts
treated with exogenous IL-6 or IL-8 did not display p53 attenuation
(Figure 2, C and D), as did treatment with GRO-α (data not shown).
However, IL-1β treatment in contrast specifically repressed p53 protein
levels in ovarian fibroblasts (Figure 1E). To address the mechanisms
of IL-1β–mediated p53 suppression, we examined if the repressed
level of p53 protein by IL-1β is mediated by p65, as IL-1β is a known
potent inducer of the NF-κB signaling pathway. We treated the p65
knockdown fibroblasts and the parental fibroblasts with IL-1β, but
we failed to detect major change in the p53 protein level when p65
was knocked down (Figure W2). These results demonstrated that
IL-1β–mediated repression of p53 protein may operate through a
p65-independent pathway.
Elevated Expression of IL-1β/IL-1R1 or Loss of p53
Expression in Stromal Fibroblasts Predicts Poor
Survival in Patients with Ovarian Cancer
Next, we reasoned that IL-1β, IL-1R1, and p53 may be able to
impact the clinical outcome of patients if this signaling axis plays a
critical role in ovarian tumorigenesis. Toward this end, we examined
the prognostic significance of expression of IL-1β and IL-1R1 in human
ovarian cancer using an ovarian cancer tissue array of 527 patients
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linked to detailed pathologic and clinical outcome information. Up-
regulation of IL-1β expression was observed in the ovarian cancer
epithelium (Figure 2B) relative to basal expression in fallopian tubal
epithelium (Figure 2A). Similarly, IL-1R1 was elevated in both ovarian
cancer epithelial cells and CAFs (Figure 2D) compared to basal ex-
pression levels observed in normal fallopian tubal epithelial cells (Fig-
ure 2C). Moreover, elevated ovarian cancer epithelial cell cytoplasmic
and plasma surface expression of both IL-1β (Figure 2E ) and its re-
ceptor IL-1R1 (Figure 2F ) significantly predicted reduced overall
ovarian cancer patient survival. Similarly, elevated immunodetection
of both IL-1β (Figure 2G ) and its receptor IL-1R1 (Figure 2H ) in
ovarian CAFs significantly predicted poor ovarian cancer patient over-
all survival. Complete patient clinicopathologic factors and indicators
are shown in Tables W1–W5. Our analysis showed a significant corre-
lation between ovarian cancer histologic type (histotype) and elevated
expression of IL-1β (P < .033; Table W1) or IL-1R1 (P < .016;
Table W3), as well as a significant cross-correlation between elevated
expression of these factors in the oncogenic epithelium and the tumor
stroma (P < .0001; Table W5). Therefore, our findings demonstrated
that the IL-1β/IL-1R1 chemokine signaling axis is indeed critical to
ovarian cancer patient outcome.
To examine the effect of p53 attenuation in stromal fibroblasts on
clinical outcome in patients with ovarian cancer, we first examined
p53 expression levels in two independent normal ovarian fibroblast
primary cell lines, NOF150 and NOF151, as well as in independent
CAF cell lines, CAF147 and CAF187. Relative to wild-type p53 pro-
tein levels in normal ovarian fibroblasts, we observed a significant
decrease in CAF p53 expression in two separate lines (Figure W3),
demonstrating downregulated p53 protein in CAFs. Next, we exam-
ined whether p53 expression is also attenuated in ovarian CAFs in vivo
by determining the level of p53 immunoreactivity in the nuclei of
CAFs within microarrays containing normal ovary, normal fallopian
tube, and ovarian cancer tissue. Relative to a robust population of
p53 nuclear-positive fibroblasts (red arrowheads) and epithelial cells
( green arrowheads) in normal ovarian or fallopian tube tissue (Figure 3,
A and B, respectively), very weak or negligible nuclear p53 staining was
observed in ovarian CAFs (red arrowheads) proximal to strongly posi-
tive high-grade serous ovarian carcinoma epithelial cells ( green arrow-
heads; Figure 3, B and D). These findings were anticipated due to a
high rate of p53 oncogenic mutation in ovarian cancer cells. Moreover,
late-stage, high-grade serous ovarian carcinoma patients with low or
negative p53 nuclear expression in their CAFs displayed significantly
reduced overall survival (P = .018; Figure 3E). Thus, our data dem-
onstrated that the level of p53 expression in ovarian CAFs is predic-
tive of poor ovarian cancer patient outcome. Collectively, these data
strongly designate IL-1β and p53 as key signaling molecules in stromal
fibroblasts in vivo, with alteration in expression significantly impacting
patient clinical outcome.
p53 Attenuation in Ovarian Fibroblasts Leads to Elevated
Expression and Secretion of Chemokines in an NF-κB
p65–Dependent Fashion
To test the direct effect of p53 on phenotypic conversion of normal
fibroblasts to a protumorigenic phenotype, p53 was forcibly attenu-
ated in normal ovarian fibroblasts through stable knockdown [28].
Attenuation of the p53 tumor suppressor in normal ovarian fibroblasts
specifically increased expression of the immunoregulators IL-8, IL-6,
GRO-α, precursor and mature secreted forms of IL-1α and IL-1β
(Figure 4A), as well as a panel of other chemokines, receptors, and
microenvironment activators (Figures W4 and W5). As these are all
downstream target genes of NF-κB transcriptional activation, our
data indicated that p53 suppression may involve NF-κB signaling
in stromal fibroblasts similar to oncogenic RAS activation in ovarian
epithelial cells [23]. To directly test this hypothesis, we examined p65
protein level in both the cytoplasm and nucleus following knockdown
of p65 gene expression in the presence or absence of p53 knockdown.
As shown in Figure 4B, in hTERT (hT) immortalized fibroblasts, p53
is primarily located in the cytoplasm; the expression of p65 is largely
Figure 1. p53 attenuation in ovarian fibroblasts is mediated by ovarian cancer cell–secreted IL-1β in vitro. Normal ovarian fibroblasts
were treated for 24 hours with conditioned media from either malignant ovarian cancer SKOV3 cells (A) or HRAS-transformed ovarian
surface epithelial T29H cells (B) and total cell lysate was harvested every 4 hours for Western blot (N = 3). Normal ovarian fibroblasts
were treated with increasing concentrations of exogenous, recombinant human IL-6 (C), IL-8 (D), and IL-1β (E) for 48 hours, after which
total cell lysate was harvested for Western blot (N = 3).
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undetectable, while the serine 276 phosphorylation form (S276) of
p65 is readily detectable. Knockdown of p53 expression increased
the nuclear expression of p65 (hTp53i) specifically phosphorylated
at serine 276, as compared with the hT lane control (Figure 4B).
These results suggest that p53 repression activates nuclear-localized,
S276-phosphorylated p65, and phospho-modification at this residue
enhances NF-κB p65 transcriptional activity by facilitating interac-
tion with the transcriptional co-activator p300/CBP [29]. Our results
showed that the p53 knockdown in the fibroblast upregulates expres-
sion of several inflammatory cytokines (Figure 4A, lanes 1 and 3);
however, the p65 knockdown almost completely abolishes these effects
(lane 4). On the basis of these data, we believe that the up-regulation
of cytokines by p53 knockdown is largely dependent on p65, although
we cannot completely rule out the role of p50 and inhibition of
nuclear factor kappa-B kinase subunit β (IKKβ) in this process. We also
observed a concurrent increase in SOCS1, a downstream p53-binding
Figure 2. The IL-1β/IL-1R1 signaling axis is highly elevated in ovarian cancer and correlates with poor ovarian cancer patient survival. Back-
ground IL-1β IHC detection is observed in both the epithelium and stromal compartment of normal ovarian cyst (A), as opposed to highly
elevated IHC staining in both compartments in ovarian cancer tissue (B). IL-1β cognate receptor IL-1R1 displays a similar pattern of back-
ground detection in normal ovarian cyst tissue (C), compared to elevated staining in ovarian cancer epithelial cells and CAFs (D). Kaplan-
Meier patient overall survival analysis curves (E–H) for ovarian carcinoma patients show reduced survival time as a function of (E) ≥85%
IL-1β expression in epithelial cancer cells (P = .033; N = 397), (F) ≥80% IL-1R1 expression in epithelial cancer cells (P = .003; N = 406),
(G)≥85% IL-1β expression in ovarian cancer fibroblasts (P= .024; N = 204), and (H)≥10% IL-1R1 expression in ovarian cancer fibroblasts
(P = .002; N = 231).
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partner modulating the senescence response [30]. As anticipated, we
detected a concurrent increase in the level of expression of IL-1α, IL-
1β, IL-6, and IL-8 in p53-attenuated fibroblasts (Figure 4B). Further-
more, we observed a corresponding increase in the level of transcripts
following inhibition of p53 alone or double inhibition of p53 and
p65 (Figure 4C). Additionally, as shown in Figure 5, A to F , we exam-
ined the level of chemokine and growth factor extracellular secretion by
ELISA for IL-1β, IL-6, GRO-α, IL-1α, IL-8, and VEGF, respectively.
All factors displayed significantly increased detection in p53-attenuated
normal ovarian fibroblasts, demonstrating enhanced secretion of these
factors to the microenvironment. Collectively, our results establish that
p53 repression directly activates phosphorylation of p65 at S276, altering
the phenotype of ovarian fibroblasts through increased expression, and
elevated extracellular secretion, of potent inflammatory modulators, al-
lowing for paracrine interaction with local cancer cells or other cell types.
p53 Attenuation Facilitates Protein Complex Formation
between p53 and NF-κB p65 and Transcription Activation
of NF-κB in Ovarian Fibroblasts
To further characterize the mechanism by which p53 regulates
NF-κB–mediated transcription, we tested whether p53 forms a pro-
tein complex with NF-κB p65 in vitro by co-IP. A high level of
p53 protein was detected in wild-type normal ovarian fibroblasts
Figure 3. p53 attenuation in ovarian CAFs correlates with reduced patient survival. IHC detection indicated healthy, elevated nuclear expres-
sion of p53 in fallopian tube (A) or ovarian cyst (B) epithelial (green arrowheads) and stromal compartment fibroblasts (red arrowheads).
(C and D) In contrast, ovarian cancer tissue IHC staining indicated highly increased p53 detection in cancer epithelial cell nuclei (green arrow-
heads), with significantly attenuated p53 nuclear expression in ovarian CAFs (red arrowheads). For micrographs A to D:magnification, ×400;
scale bars, 50 μm; p53 antibody dilution of 1:75. (E) Kaplan-Meier analysis indicated that overall survival rates were significantly lower for
late-stage, high-grade serous ovarian carcinoma patients with CAF displaying very low nuclear levels of p53 (P = .018; N = 301).
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regardless of the presence or absence of p65 knockdown. However,
p65 (both total and phospho-forms) associated directly with the iso-
lated p53 protein complex only when p53 levels were repressed (Fig-
ure 6A, left panel ). In contrast, when p65 was the moiety being
immunoprecipitated, p53 was undetectable regardless of the status
of knockdown targeting either p53 or p65, except for a faint p53-p65
interaction in hTERT-immortalized normal ovarian fibroblasts
(Figure 6B, right panel ). These data revealed a unidirectional signal from
p53 to p65, evidenced by the observation that loss of p53 increased the
level of total and S276-phosphorylated p65 in ovarian fibroblasts, with-
out a reciprocal activation of p53 in the absence of p65. Thus, our results
signify that p65 not only interacts within a stable complex with p53 but
is also itself a downstream target of this interaction. To directly test
whether p53 repression alters transcriptional activation of NF-κB, we
used an NF-κB–responsive reporter construct. Parental normal ovarian
fibroblasts (hT), those with p65 knockdown, p53 knockdown, or both,
were transiently co-transfected with plasmids containing promoter ele-
ments engineered with either two wild-type or two mutant sites for
NF-κB binding for dual-luciferase reporter detection assay. Our data
show that p53 attenuation in ovarian fibroblasts strongly activated tran-
scription of the wild-type NF-κB–responsive promoter, in comparison
to nearly undetectable activity in p53-inhibited normal ovarian fibro-
blasts expressing the mutant NF-κB promoter or to p53-p65 double-
knockdown normal ovarian fibroblasts expressing wild-type NF-κB
promoter (Figure 6B). Collectively, these findings demonstrate that
p53 normally suppresses activation of NF-κB in ovarian fibroblasts.
Moreover, repression of p53 protein levels facilitates protein complex
formation with NF-κB p65, phosphorylation of p65 at S276, and
thus downstream activation of multiple inflammatory cytokine and
chemokine targets.
p53 Attenuation in Fibroblasts Facilitates Ovarian Tumor
Growth In Vivo in an NF-κB p65–Dependent Manner
We next investigated the significance of secreted interaction be-
tween p53-attenutated ovarian fibroblasts and ovarian cancer cells
during tumor growth in vivo [23]. p53-attenuated ovarian fibroblasts
( green curve) significantly increased the tumorigenic growth from
immortalized, nontumorigenic ovarian epithelial cells (T29) (P <
.0001), compared to parental T29 cells (blue curve; P < .005; Fig-
ure 7A). Notably, double attenuation of both p53 and p65 (purple
curve), or only p65 knockdown (red curve), in hTERT-expressing
normal ovarian fibroblasts was sufficient to completely abrogate the
growth-stimulatory effect of p53-attenuated normal ovarian fibro-
blasts exerted on T29 cells. The tumors were significantly infiltrated
by neutrophils (arrow points, Figure W6). These results indicated
that the inflammatory cells were recruited to the tumors and may con-
tribute to the tumor growth. Similarly, p53-attenuated ovarian fibro-
blasts ( green curve) significantly increased the tumorigenic growth from
the SKOV3 ovarian cancer cell line, relative to all control co-injections
(Figure 7B; P < .005). Attenuation of both p53 and p65 in ovarian
fibroblasts (purple curve) completely abrogated the effect of p53-
attenuated fibroblastic stimulation on SKOV3 tumor growth. These
results demonstrate that p53-reduced normal ovarian fibroblasts acti-
vate NF-κB–mediated chemokine and growth factor secretion, indeed
exerting a robust promotion of tumor growth in vivo.
Collectively, our data suggest a novel model for ovarian epithelial
cancer cells working in synergy with stromal fibroblasts through an
inflammatory chemokine (Figure 7C): Following oncogenic activation
mediated by mutated RAS or loss of a tumor suppressor gene like
TP53, epithelial cancer cells express a high level of IL-1β, which stimu-
lates IL-1R1 on adjacent stromal fibroblasts leading to attenuation of
Figure 4. p53 attenuation in normal ovarian fibroblasts elevates expression of critical secreted paracrine communication chemokines
and ECM remodeling factors in an NF-κB p65–dependent fashion. (A) Attenuation of p53 in ovarian fibroblasts increases expression of
IL-8, IL-6, GRO-α, both immature and mature secreted forms of IL-1α and IL-1β, TRAF-6, and SOCS1, relative to γ-tubulin total cell levels.
Double attenuation of p53 and NF-κB p65 either disrupt this stimulation (nearly all chemokines shown and SOCS1) or enhance the stimu-
lation (TRAF-6), indicating that p53 suppression requires p65 signaling to stimulate chemokine secretion. (B) Cytoplasmic (C) and nuclear
(N) fractionation before protein lysate harvest indicates that p53 repression activates nuclear localization of p65 phosphorylated at
serine 273 and confirms elevated cytoplasmic expression of chemokines IL-1α, IL-1β, IL-6, and IL-8 following p53 attenuation that is primarily
dependent on p65 as a driving mechanism, relative to stable cytoplasmic levels of HSP-90 and nuclear protein Lamin A/C. (C) Observations
at the translational level are confirmed at the transcriptional level by reverse transcription–polymerase chain reaction amplification of cDNA
from total RNA lysates following p53, or p53 and p65, attenuation, relative to stable β-actin RNA levels. Each blotting result indicates
representative results from N = 3 experiments.
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p53 tumor suppressor protein levels. Repression of p53 leads to trans-
activation of NF-κB, which in turn activates the transcription and
release of multiple key immunomodulatory chemokines, including
IL-6, IL-8, GRO-α, IL-1β, as well as VEGF. These proinflammatory
and proangiogenic factors synergistically interact with each other to
generate a tumor-prone microenvironment, jointly fostering a para-
crine synergy with cancer cells to support malignant tumor progression
mimicking an unhealed wound.
Discussion
Twenty-five years ago, Dvorak first described that human cancer is
similar to an “unhealed” wound [31]. Cancer epithelial cells are highly
effective in their mutation-selected ability at co-opting the stromal
microenvironment, by inappropriately amplifying the normal inflam-
matory and cellular processes of wound healing to facilitate cancer
progression, directly initiating cancer cell proliferation, angiogenesis,
and invasion [32–34]. More specifically, this perturbation to a state
of chronic repair relies on reciprocal paracrine interaction between
epithelial tumor cells and neighboring stromal fibroblasts [35]. Al-
though this is a universal, heterotypic signaling paradigm across tumor
types that leads to a stromal inflammatory recruitment [29], details
pertaining to the underlying mechanism for this well-described synergy
between tumor and stroma remain largely uncharted. Here, we dem-
onstrate that IL-1β mediates this paracrine communication between
ovarian epithelial cancer cells and neighboring stroma. In addition,
we show that the IL-1β/IR-1R1 signaling axis is highly elevated in
both the cancer epithelium and cancer stroma of ovarian cancer patient
tissue samples in vivo and that increased IHC detection of both ligand
and receptor significantly predicts reduced overall patient survival.
Further, we show that due to ovarian cancer cell–elevated expression
of IL-1β, activation of IL-1R1 in stromal fibroblasts leads to repression
of p53 and a concurrent activation of NF-κB transcriptional targets
like IL-8, GRO-α, IL-6, and IL-1β. Therefore, IL-1β may act in syn-
chrony with other cytokines to synergize its effect on the tumor pro-
motion. It is interesting to note that fibroblasts with p53 knockdown
are quite significant in promoting tumor growth from T29 cells while
the effect on SKOV3 cells was minimal, as the T29 cell line was
immortalized with SV40 T/t antigens and the human catalytic subunit
of telomerase and is not tumorigenic. However, the human epithelial
Figure 5. p53 inhibition in ovarian fibroblasts promotes extracel-
lular secretion of inflammatory modulators of ovarian cancer in
a p65-dependent manner. ELISA, following harvest of growth
media conditioned for 48 hours by normal ovarian fibroblasts ex-
pressing hTERT (hT), p65 attenuation (hTp65i), p53 attenuation
(hTp53i), or p53 and p65 attenuation (hTp53ip65i) viral constructs,
was used to measure extracellular secretion of IL-1β (A), IL-6 (B),
GRO-α (C), IL-1α (D), IL-8 (E), and VEGF (F). All ELISA data were
standardized according to detection of known concentrations of
recombinant proteins respective to each molecule listed and nor-
malized to total, viable cell number at the time of conditioned
medium collection.
Figure 6. Interaction between p53 and NF-κB p65 governs the
activated secretion profile in ovarian fibroblasts. (A) Co-IP from pre-
cleared lysates of the same cell lines listed above using either
p53-linked or p65-linked agarose beads, followed by Western
immunoblot (IB) analysis for p65, phospho-p65 at serine 276, or
p53 (N = 2). (B) Normal ovarian fibroblasts expressing hTERT, p65
attenuation, p53 attenuation, or p53 and p65 attenuation viral con-
structs were transiently co-transfected with dual-luciferase reporter
plasmids bearing either wild-type (wt) or mutated (mut) NF-κB
promoter driving firefly luciferase [48] and control plasmid bear-
ing CMV intermediate promoter controlling Renilla luciferase (pRL-
CMV). The ratio of detection of firefly/Renilla luciferases in relative
light units was standardized according to total protein concentration
for each lysate (N = 4).
Neoplasia Vol. 15, No. 4, 2013 Interleukin-1β Promotes Ovarian Tumorigenesis Schauer et al. 417
ovarian cancer cell line SKOV3 is highly tumorigenic and aggressive.
The effects of p53 knockdown fibroblasts are quite significant on the
tumor promotion from T29 cells, suggesting that the proinflammatory
fibroblast may play important roles in oncogenic transformation rather
than in the promotion of advanced tumors. Moreover, our findings
revealed that targeted and sustained knockdown of p53 protein in
normal ovarian fibroblasts in vitro fosters a highly activated stromal
phenotype characterized by a significant increase in proliferation and
progression through the cell cycle, with concurrent inhibition of apo-
ptosis. Therefore, our report demonstrates the critical function of
IL-1β as a secreted mediator used by cancer epithelial cells to syner-
gistically activate adjacent stroma to a proinflammatory and protumori-
genic phenotype.
Almost all high-grade ovarian serous carcinoma cells acquire TP53
mutations [10], and multiple reports have indicated that altered p53
expression in cancer fibroblasts, perhaps not mutational events, act
to promote stromal cell involvement in stimulating tumorigenesis
[36]. Indeed, evidence suggests that human prostate and breast can-
cer fibroblasts express a nonmutated, but functionally deficient, form
of p53 [37,38], expanding on mouse and cell-based studies pointing
to a selective mechanism exerted by tumorigenic epithelial cells for
synergistic growth and development with p53-attenuated fibroblasts
[13,39–42]. Offering novel evidence of this mechanism in the con-
text of ovarian cancer, we show that specifically IL-1β secreted by
ovarian cancer epithelial cells acts as a critical signal instructing nor-
mal ovarian fibroblasts to repress p53, indicating that p53 in stromal
fibroblasts is a key sensor for perceiving and interpreting this signal.
Furthermore, attenuated expression of p53 in fibroblasts significantly
predicts reduced survival among serous ovarian carcinoma patients.
Therefore, these findings suggest that repression of p53 in ovarian
fibroblasts may be as crucial to ovarian cancer progression as TP53
mutational events in epithelial tumor cells.
The NF-κB pathway is well known for the central role it plays in
human cancer, in which hyperactivation is a common occurrence due
primarily to the promotion this exerts on cell cycle progression, anti-
apoptosis, angiogenesis, and inflammatory activation [20]. NF-κB has
been shown to be functionally antagonistic with p53 in multiple
tumor types [43]. Moreover, it has been observed across disparate
tumor types that constitutive activation of the NF-κB pathway leads
in part to repression of wild-type p53 tumor suppressor function
[44]. Interestingly, this mutual repression balancing act between p53
and p65 involves competition for critical nuclear interaction part-
ners [45], including the ARF/BRCA1/ATR/Chk1 tumor suppressor
and proliferation inhibitory complex [46] and the stress activation–
responsive nuclear protein proenkephalin controlling apoptosis [47].
Our study reveals a novel mechanism of interaction between p53
and NF-κB in activation of stromal fibroblasts. In contrast to the pre-
viously described mutual activation between p53 and NF-κB in cancer
cells, p53 repression in ovarian fibroblasts increased the total and
S276-phosphorylated p65; the latter is nuclear localized and this
may facilitate the interaction with nuclear p53, thereby facilitated
formation of a p53/phospho-p65 protein complex, leading to a
Figure 7. p53 attenuation in ovarian fibroblasts promotes in vivo
tumorigenesis through an NF-κB p65–dependent mechanism.
(A) p53-attenuated ovarian fibroblasts (green curve) significantly
increased the tumorigenic potential of preneoplastic ovarian sur-
face epithelial T29 cells, compared to hTERT-immortalized ovarian
fibroblast stimulation of T29 cells (blue curve), relative to all listed
control co-implantations. Double attenuation of p53 and p65 (purple
curve) or only p65 knockdown (red curve) completely ameliorated
the effect of p53 attenuation. (B) p53-attenuated ovarian fibroblasts
(green curve) significantly decreased the tumorigenic lag phase of
malignant ovarian cancer SKOV3 cells, relative to all control co-
injections. p53 and p65 co-attenuation (purple curve) completely
abrogated the effect of p53 attenuation; * indicates P < .005 and
** indicates P < .0001 by calculating ANOVA comparing p53-
attenuated fibroblast co-injections with either hTERT-only, p65
knockdown, or SKOV3-only controls (N = 8 injections per experi-
mental group orN =3 injections per control group). (C)Model based
on the hypothesis and results demonstrating that IL-1β secreted
from ovarian cancer epithelial cells effectively attenuates adjacent
ovarian fibroblast p53 tumor suppressor protein levels, which tran-
scriptionally activates NF-κB promoter leading to the transcriptional
activation and release of key chemokines and activator molecules
that synergistically act in paracrine on the initiator ovarian epithelial
cells to further alter the phenotype to that of invasive andmetastatic.
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p65-dependent transcriptional induction at the NF-κB promoter,
phenotypically switching ovarian fibroblasts to potent stimulators of
ovarian epithelial cell transformation and tumor growth. Therefore,
p53-mediated repression of p65 transcriptional activation is a critical
sensor in ovarian fibroblasts that capacitates the cancer cell–secreted
signal IL-1β to induce a tumor-prone phenotype and generate a
microenvironment selectively conducive to malignant progression.
Our results provide a long-sought mechanism characterizing how
epithelial cancer cells, fibroblasts, and inflammation are coordinately
regulated as an “unhealed wound” to generate a malignant phenotype.
Elucidating additional details regarding the mechanism of regulation
and interaction among IL-1R1 signaling, p53 function, and NF-κB
p65 transactivation in ovarian fibroblasts is essential. New findings
along these lines would increase our understanding of the role that
the stroma plays in ovarian tumorigenesis and aid in the development
of novel therapeutic approaches for ovarian cancer as well as other solid
epithelial tumors.
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Figure W1. Human telomerase–immortalized normal ovarian fibro-
blasts display elevated proliferation and extended replication com-
pared to primary parental fibroblasts. (A) Ovarian fibroblast lines
infected and selected to overexpress the catalytic subunit of human
telomerase (hTERT). (B) hTERT expression allows for sustained
population doublings and continuous cell growth. (C) hTERT expres-
sion in ovarian fibroblast lines significantly increases proliferative
capacity measured over 24 and 48 hours (N = 8 per column).
Figure W2. Expression of p53 protein in normal ovarian fibroblasts
and ovarian fibroblasts with p65 knockdown in the presence or
absence of IL-1β. Normal ovarian fibroblasts (hT) or ovarian fibro-
blasts with p65 knockdown (hTp65i) were treated with recombinant
human IL-1β for 48 hours, after which total cell lysate was harvested
for Western blot (N = 3).
Table W1. Correlations between the Expression of IL-1β in Ovarian Cancer Patient Stromal Cells and Clinicopathologic Factors.
Characteristic No. of Patients (%) P Value*
<85% IL-β–Positive Stromal Cells ≥85% IL-β–Positive Stromal Cells Total No.
Histologic type 0.033
High-grade serous carcinoma 222 (70.5) 93 (29.5) 315
Low-grade serous carcinoma 5 (41.7) 7 (58.3) 12
Endometrioid carcinoma 26 (74.3) 9 (25.7) 35
Others 37 (84.1) 7 (15.9) 44
Histologic type 0.112
Serous carcinoma 227 (69.4) 100 (30.6) 315
Endometrioid carcinoma 26 (74.3) 9 (25.7) 35
Others 37 (84.1) 7 (15.9) 44
Endometrioid carcinoma grade 0.016
High grade 25 (83.3) 5 (16.7) 30
Low grade 1 (20.0) 4 (80%) 5
FIGO disease stage 0.122
Stage I 26 (86.7) 4 (13.3) 30
Stages II–IV 264 (70.2) 112 (29.8) 376
Age at diagnosis (years) 0.124
>60 134 (67.7) 64 (32.3) 198
≤60 156 (75.0) 52 (25.0) 208
Ascites 0.026
Yes 158 (65.8) 82 (34.2) 240
Minimal 21 (75.0) 7 (25.0) 28
No 48 (80.0) 12 (20.0) 60
Unknown 63 (80.8) 15 (34.2) 78
Clinical response 0.947
Complete 147 (70.3) 62 (29.7) 209
None 44 (72.1) 25 (27.9) 73
Partial 75 (73.5) 27 (26.5) 102
Unknown 24 (53.1) 10 (46.9) 34
CA125 0.399
<500 115 (74.2) 40 (25.8) 155
≥500 138 (71.1) 56 (28.9) 194
Unknown 37 (71.4) 20 (28.6) 57
The histologic category “Others” includes mucinous carcinoma (5 cases), clear cell carcinoma (11 cases), transitional cell carcinoma (9 cases), malignant mixed Müllerian tumor (9 cases), undifferentiated
carcinoma (9 cases), and mixed-type carcinoma (1 case).
*P values were calculated by Fisher’s exact test.
Table W2. Elevated IL-1β Stromal Cell Expression Reduces Ovarian Cancer Patient Overall Survival but Does Not Affect Disease-Free Survival.
IL-β Expression No. of Patients Median Survival (95% CI; Years) Overall Survival Rate (95% CI) P Values*
3 Years 5 Years 10 Years
<85% 284 5.0 (3.7, 6.4) 0.64 (0.58, 0.70) 0.51 (0.44, 0.57) 0.38 (0.30, 0.45)
0.024
≥85% 113 3.5 (2.7, 4.2) 0.58 (0.48, 0.67) 0.32 (0.22, 0.42) 0.25 (0.15, 0.35)
IL-β Expression No. of Patients Median Survival (95% CI; Years) Disease-Free Survival Rate (95% CI) P Values
3 Years 5 Years 10 Years
<85% 149 1.6 (1.1, 2.0) 0.34 (0.26, 0.42) 0.25 (0.18, 0.32) 0.21 (0.14, 0.28)
0.093
≥85% 55 0.9 (0.7, 1.1) 0.23 (0.11, 0.34) 0.17 (0.06, 0.27) (<0.04, <0.23)
*P values were derived from the log-rank test.
Table W3. Correlation between IL-1R1 Expression and Ovarian Cancer Patient Clinicopathologic Factors.
Characteristic IL-1R1 Expression in Tumor Cells IL-1R1 Expression in Stromal Cells
No. of Patients (%) No. of Patients (%)
<80% ≥80% Total No. P Value* <10% ≥10% Total No. P Value*
Histologic type 0.436 0.655
High-grade serous carcinoma 111 (34.3) 213 (65.7) 324 153 (47.7) 168 (52.3) 321
Low-grade serous carcinoma 2 (16.7) 10 (83.3) 12 4 (33.3) 8 (66.7) 12
Endometrioid carcinoma 13 (43.3) 17 (56.7) 30 16 (55.2) 13 (44.8) 29
Others 16 (32.0) 34 (68.0) 50 23 (48.9) 24 (51.1) 47
FIGO disease stage 0.016 0.208
Stage I 14 (45.2) 17 (54.8) 31 15 (50.0) 15 (50.0) 30
Stage II 7 (29.2) 17 (70.8) 24 8 (33.3) 16 (66.7) 24
Stage III 105 (37.2) 177 (62.8) 282 141 (50.9) 136 (49.1) 277
Stage IV 16 (20.3) 63 (79.7) 79 32 (41.0) 46 (59.0) 78
Age at diagnosis (years) 0.756 1.000
>60 74 (35.1) 137 (64.9) 211 99 (47.8) 108 (52.2) 207
≤60 68 (33.2) 137 (66.8) 205 97 (48.0) 105 (52.0) 202
Ascites 0.074 0.065
Yes† 88 (31.9) 188 (68.1) 276 124 (45.4) 149 (54.6) 273
No† 27 (44.3) 34 (55.7) 61 36 (59.0) 25 (41.0) 61
Unknown 27 (34.2) 52 (65.8) 79 36 (48.0) 39 (52.0) 75
Clinical response 0.980 0.705
Complete 74 (33.8) 145 (66.2) 219 100 (46.5) 115 (53.5) 215
None 21 (33.9) 41 (66.1) 62 27 (44.3) 34 (55.7) 61
Partial 35 (34.0) 68 (66.0) 103 53 (52.5) 48 (47.5) 101
Unknown 12 (37.5) 20 (62.5) 32 16 (50.0) 16 (50.0) 32
CA125 0.329 0.094
<500‡ 66 (38.4) 106 (61.6) 172 94 (55.0) 77 (45.0) 171
≥500‡ 66 (33.3) 132 (66.7) 198 89 (45.9) 105 (54.1) 194
Unknown 10 (64.3) 36 (35.7) 46 13 (64.3) 31 (35.7) 44
The histologic category “Others” includes mucinous carcinoma, clear cell carcinoma, transitional cell carcinoma, malignant mixed Müllerian tumor, undifferentiated carcinoma, and mixed-type carcinoma.
*P values were calculated by Fisher’s exact test.
†Ascites versus non-ascites.
‡CA125 <500 IU/ml versus CA125 ≥ 500 IU/ml.
Table W4. IL-1R1 Expression Correlates with Reduced Ovarian Cancer Patient Overall Survival but Not with Altered Disease-Free Survival.
IL-1R1 Expression in Tumor Cells IL-1R1 Expression in Stromal Cells
<80% ≥80% <10% ≥10%
No. of patients 140 266 194 205
Mean survival (95% CI; years) 6.1 (3.3, 9.0) 3.5 (2.9, 4.2) 5.8 (2.3, 9.4) 3.5 (2.9, 4.2)
Overall Survival Rate (95% CI)
3 years 0.73 (0.65, 0.81) 0.59 (0.52, 0.65) 0.70 (0.63, 0.77) 0.58 (0.50, 0.65)
5 years 0.59 (0.49, 0.69) 0.48 (0.41, 0.54) 0.54 (0.46, 0.62) 0.39 (0.31, 0.46)
10 years 0.35 (0.20, 0.49) 0.29 (0.22, 0.36) 0.35 (0.15, 0.54) 0.26 (0.18, 0.33)
P values* P = 0.003 P = 0.002
No. of patients 83 148 107 120
Mean survival (95% CI; years) 1.4 (0.9, 1.8) 1.4 (1.0, 1.8) 1.5 (0.9, 2.1) 1.5 (1.1, 1.9)
Disease-free survival rate (95% CI)
3 years 0.35 (0.24, 0.45) 0.36 (0.28, 0.44) 0.36 (0.27, 0.45) 0.37 (0.28, 0.46)
5 years 0.29 (0.18, 0.39) 0.29 (0.21, 0.36) 0.28 (0.19, 0.36) 0.31 (0.22, 0.39)
10 years 0.23 (0.12, 0.33) 0.25 (0.17, 0.32) 0.24 (0.15, 0.33) 0.25 (0.17, 0.33)
P values* P = 0.964 P = 0.974
*P values were derived from the log-rank test.
Table W5. Correlation of IL-1R1 Expression between the Tumor and Tumor Microenvironment.
Tumor Group Stromal Group
Tumor group Pearson correlation 1 0.578
Sig. (two-tailed) P < .0001*
Sum: squares and cross-products 93.529 55.868
Covariance 0.225 0.137
N 416 409
Stromal group Pearson correlation 0.578 1
Sig. (two-tailed) P < .0001*
Sum: squares and cross-products 55.868 102.073
Covariance 0.137 0.250
N 409 409
*Correlation is significant at the 0.01 level (two-tailed).
Figure W3. Forcible attenuation of p53 in ovarian fibroblasts yields elevated proliferative status, increased cell cycle progression, and
decreased apoptosis in a p65-dependent manner. (A) p53 status of parental normal ovarian fibroblast lines NOF150 and NOF151, human
telomerase–expressing lines NOF150hT and NOT151hT, and CAF lines CAF187 and CAF147 (DTI). (B) Proliferation of ovarian fibroblast
lines (*P < .05, N = 4, Student’s t test). (C) Apoptotic status of ovarian fibroblast lines secreted into early and late apoptosis (*P < .0001
by two-way ANOVA; N = 2). (D) Cell cycle progression status of ovarian fibroblast lines according to G1 checkpoint, DNA synthesis (S),
and G2 checkpoint according to PI detection through flow cytometry (*P < .0001 by two-way ANOVA; N = 2).
Figure W4. Attenuation of p53 in fibroblasts activates secretion
and production of a panel of inflammatory response mediators.
Forcible, viral-mediated stable shRNA attenuation of p53 in ovarian
fibroblasts increases expression of chemokine receptors IL-1R1,
CXCR2, and GRO-α, both immature and mature secreted forms of
IL-1α and IL-1β, IL-6, IL-8, and VEGFA, relative to control commercial
foreskin fibroblasts (BJ) and primary parental ovarian fibroblasts,
standardized to total protein levels of β-actin.
Figure W5. Expression of p53 in the presence of GRO-α. Normal
ovarian fibroblasts were treated with increasing concentrations of
exogenous, recombinant human GRO-α for 48 hours, after which
total cell lysate was harvested for Western blot (N = 3).
Figure W6. Hematoxylin and eosin (H&E) staining of xenograft tu-
mors from T29H cells. The tumors were infiltrated by numerous
neutrophils (arrow points).
